1. INTRODUCTION
===============

Tuberculosis (TB) is a major public health concern in the developing world. According to the World Health Organization (WHO) report in 2018, TB caused an estimated 1.3 million deaths (range, 1.2--1.4 million) among Human Immunodeficiency Virus (HIV)-negative people and there were an additional 300,000 deaths from TB (range, 266,000--335,000) among HIV-positive people \[[@r1]\]. Globally, the best estimate is that 10.0 million people (range, 9.0--11.1 million) developed TB disease in 2017: 5.8 million men, 3.2 million women and 1.0 million children. WHO's list of 30 high TB burden countries accounted for 87% of the world's cases \[[@r1]\].

The annual infection rate in developing countries reached 2% or more; where as in developed countries this figure is 0.5% \[[@r2]\]. In Africa, more than 4 million people suffer from active TB and 650,000 deaths occurring every year \[[@r3]\].

According to Ethiopian national TB guidelines: relapses, failure, return after loss to follow-up and other are the four categories to define previously treated TB patients. 'Other' includes chronic re-treatment TB patients, recurrent smear-negative pulmonary tuberculosis (PTB) and extra-pulmonary tuberculosis (EPTB) \[[@r4]-[@r6]\].

Previously conducted studies have revealed that retreatment TB cases play major role in the development of drug resistance including Multidrug resistant tuberculosis (MDR-TB) which is considered to be a global threat today \[[@r4]-[@r7]\]. The threat effect of TB retreatment at individual, community and country levels both on the economy and mortality of people in Ethiopia is a great problem today \[[@r5], [@r7]\].

Different studies had identified factors determining the retreatment TB cases such as; socio-demographic factors smear result at enrolment, year of treatment, Anti-TB regimen, patient category and HIV status \[[@r8]-[@r15]\]. Therefore, this study is designed to examine both the burden of retreatment TB cases and their treatment outcomes in Nekemte Referral Hospital (NRH) and give an appropriate recommendation based on the findings.

2. MATERIALS AND METHODS
========================

2.1. Study Design and Population
--------------------------------

A retrospective cross-sectional study was conducted. All registered adult TB patients under retreatment regimen who were treated at NRH TB clinics from January 2014 to December 2017 were included in this study, while patients who had discontinued treatment due to misdiagnosis were excluded.

2.2. Sample Size Determination
------------------------------

Since the total numbers of TB patients under the retreatment regimen were only 219, all of them were included in the study.

2.3. Data Collection Process and Quality Assurance
--------------------------------------------------

Data were collected by using data collection checklists which were designed-based on the literature review of similar studies \[[@r7]-[@r11]\]. Data were obtained from TB registers and patient treatment cards. Data collection was conducted with appropriate training of the data collectors and close supervision with continuous data monitoring to keep the quality of the data.

2.4. Data Analysis and Interpretation
-------------------------------------

After data collection, data were entered into the Statistical Package for the Social Sciences (SPSS) version 20 for analysis. Descriptive statistics were calculated for all variables. Odds ratio with 95% confidence interval, along with binary and multiple logistic regression was used to assess the significance and strength of association. A P-value \<0.05 was used as statistically significant.

2.5. Definition of Terms
------------------------

The cases selected for the study (retreatment after failure, retreatment after loss to follow-up, relapse) and the outcome of these cases (cure, treatment completed, treatment failure, loss to follow-up, dead) were defined based on the standard definitions of the National TB and leprosy control program guideline of Ethiopia for the diagnosis and treatment of TB cases \[[@r5]\].

**"Retreatment after failure"** is defined as a patient who started on retreatment after the previous treatment has failed.

A patient previously treated for TB who returns to treatment having previously lost to follow-up is referred to as **"retreatment after loss to follow-up".**

A **"relapse"** case is defined as a patient who previously was declared cured or treatment completed and is diagnosed with bacteriologically-positive (sputum smear or culture).

A patient is considered **"cured"** when sputum smear examination is bacteriologically negative in the last month of treatment and on at least one previous occasion. If a patient completed treatment without having a negative bacteriological result in the last month of treatment and on at least one previous occasion, then patient is declared as **"treatment completed".** If a patient interrupted his treatment for 8 or more consecutive weeks after he/she had been on treatment for at least 4 weeks, the patient is considered as a **"loss to follow-up".**

**Treatment failure** is defined as a patient who remains or becomes again smear-positive at the end of 5 months or later during treatment. A patient is declared **"dead"** if he/she died for any reason during the course of treatment.

**Category 1:** consists mainly of new, smear-positive tuberculosis cases, but includes new smear-negative cases with extensive parenchymal lesions, and new cases with severe extrapulmonary tuberculosis. The treatment regimen for this category is: 2ERHZ/4RH.

**Category 2:** smear-positive cases who have already received treatment for at least one month in the past and who need to receive re-treatment. The treatment regimen for this category is: 2SERHZ/1ERHZ/5ERH

2.6. Ethics Approval and Consent to Participate
-----------------------------------------------

Ethical clearance was obtained from the Institutional Research Ethics Review Committee of Wollega University, College of Health Sciences. This committee wrote a formal letter of permission to Nekemte Referral Hospital to seek its cooperation and access to the data. Permission was obtained from the medical director's office of the hospital. Confidentiality was ensured during the data collection, thus the name of the patient were not recorded in the data collection checklist.

3. RESULT
=========

3.1. Socio-demographic Characteristics and Clinical Characteristics
-------------------------------------------------------------------

From January 2014 to December 2017, a total of 1807 tuberculosis patients were registered at NRH, of these 219 adult patients were registered as retreatment case. Thus, in this study, the prevalence of retreatment cases was 12.12%. The mean age of the study participants was 37.91 [+]{.ul} 13.2. From all 219 patients evaluated for treatment outcomes, 76(34.7%) were cured, 70(32%) treatment completed, 47(21.5%) were failed and 5 (2.3%) died. Drug regimen used were category 1(2ERHZ/4RH) in 111(50.7%) patients and category 2 (2SERHZ/1ERHZ/5ERH in 108(49.3%) patients (Table **[1](#T1){ref-type="table"}**).

3.2. Treatment Outcomes
-----------------------

Of the 219 patients treatment outcome is known for 199 patients, thus transferred outpatients (20) were excluded from the analysis. Treatment outcomes were sorted into successful (cure and completed therapy) and unsuccessful (treatment failure, loss to follow-up and died). Of the patients with unsuccessful treatment outcomes, 40(75.5%) were from patients with relapse, 8 (15.1%) were from patients with retreatment after failure and 5(9.4%) were from patients with retreatment after loss on follow-up. From all patients with unsuccessful treatment outcomes, a higher proportion 24(45.3%) were registered in year 2016 (Table **[2](#T2){ref-type="table"}**).

3.3. Determinants of TB Retreatment Outcome
-------------------------------------------

The bivariable analysis showed that sex and AFB result at 5th month and drug regimen were associated with poor treatment outcomes Table **[3](#T3){ref-type="table"}**. Variable with P-value \< 0.25 (like sex, AFB result at 2^nd^ /3^rd^ month, AFB result at 5^th^ month and drug regimen) and known risk factors of TB outcomes like age and HIV status were entered into multivariable analysis. Factors that were significantly associated with poor treatment outcome at p\<0.05 in multivariable analysis were positive AFB result at 5^th^ month and patients on category 1(2ERHZ/4RH). While dealing with these factors, patients who had positive AFB result at 5^th^ month were 4.3 times more likely to have poor treatment outcomes when compared with patients who had negative AFB results at 5^th^ months (AOR =4.3, 95%, (1.8-10.0) p=0.001). Based on a drug regimen, patients who were on category 1(2ERHZ/4RH) were 2.1 times more likely to have poor treatment outcomes than patients on category 2 (2SERHZ/1ERHZ/5ERH) (AOR=2.1, 95% CI= (1.1-4.5) p=0.048) (Table **[3](#T3){ref-type="table"}**).

4. DISCUSSION
=============

This study aimed to assess the TB retreatment case and their outcomes in NRH. From a total of 219 patients, this study evaluated 199 patients with known treatment outcomes after excluding transferred out patients which are 20 in number and found that only 73.4% of patients had achieved successful treatment outcome. According to WHO target, treatment success rate for high burden TB countries like Ethiopia should be 90% and above. Therefore, this study indicates poor results compared to WHO target \[[@r1]\].

HIV status of the patients was also assessed with 32.9% positive status which is the same with the study done in AHMC \[[@r15]\] which are relatively same with the prevalence of HIV in the community and higher than the study done in Ethiopian Somali region \[[@r14]\]. The might be due to pastoral life style of the patients in these study areas. Studies were done in Uganda \[[@r16]\] and Benin \[[@r17]\] revealed that unknown HIV status was significantly associated with poor treatment success compared to known HIV status, however, in both studies, no statistical difference was seen between HIV- positive and HIV- negative patients on treatment outcome. In the present study, no patients with known treatment outcome were registered as unknown HIV status, but similar to the above studies there was no significant difference in treatment and success was found between HIV-positive and HIV-negative patients.

In this study, sex has not shown a statistical difference in treatment outcome. However, studies from Bangalore city of India \[[@r18]\] and Italy \[[@r19]\] had reported that male patients were more likely to have poor treatment outcomes than female patients. Similar to the present study no significant associations were observed between unsuccessful outcome and gender in other studies from the Ethiopian Somali region \[[@r14]\], AHMC \[[@r15]\] and India \[[@r20]\]. This might be due to epidemiological factors and integrated research is required to outline the relative roles played by epidemiology in this area.

Patients who had positive AFB result in 5^th^ month were 4.3 times more likely to have poor treatment outcomes when compared with patients who had negative AFB results at 5^th^ months (AOR =4.3, 95%, (1.8-10.0) p=0.001). This is due to the fact that if the patient is found smear positive at the end of the 5^th^ month of treatment, in two different specimens, the patient is declared as treatment failure.

Based on drug regimens, patients who are on category 1(2ERHZ/4RH) are more likely to have poor treatment outcomes when compared with patients on category 2(2SERHZ/1ERHZ/5ERH). This is the same with the study done in Ethiopian Somali and AMHC \[[@r14], [@r15]\]. According to Ethiopian national TB guidelines, a retreatment regimen (2SRHZE/1RHZE/5RHE) should have been used for all retreatment cases. But more than half of patients were inappropriately treated with category I regimen (2RHZE/4RH), similarly, the study was done in Uganda \[[@r21]\] and Malawi \[[@r22]\] reported that only 32% and 38% of the patients were on category II regimen respectively. The overall treatment success rate was low among retreatment TB patients receiving category I regimen suggesting that; there was a practice of inappropriate use of regimen. The reason for the inappropriateness might be due to the lack of knowledge of the health care professionals about the recommendations of the guideline and lack of adherence to the guideline.

CONCLUSION
==========

This study showed that TB retreatment case outcomes were below standard set by the World Health Organization (WHO). The main finding of the study is that half of the patients were given the wrong treatment (Category 1 - standard short course therapy) when all should have had Category 2 treatment (basically the awful WHO Category 2 regimen which involves breaking the cardinal rule of TB management which is never to add a single drug to a failing regimen - apparently this is still standard practice in Ethiopia though it has undoubtedly contributed to the development of drug resistance worldwide. Factors that were significantly associated with poor treatment outcome of retreatment patients were positive smear result of AFB result at 5^th^ month and drug regimen of category 1(2ERHZ/4RH). We recommend implementation of DOTS plus strategy both at initiation and continuation phases of treatment. To evaluate response of TB retreatment cases monitoring should be done more frequently than the recommended interval to take early action.

LIMITATIONS
===========

Limitation of this study was that the study design we used was a retrospective study which may be subjected to biases. Variables like educational level, adherence, patient-health worker communication and provider and health system related factors because of the retrospective nature of our study were not addressed. Another limitation was that the sample size we used was small.

We are grateful to the Department of Pharmacy, Wollega University for their unreserved cooperation in making this study fruitful. We are also thankful to the outpatient department nurses of Nekemte Referral Hospital for their cooperation in collecting the data and the patients who willingly participate in this study.
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###### Socio-demographic characteristics and Clinical characteristics of TB patients in Nekemte Referral Hospital, West Ethiopia, From January 2014 to December 2017 n=219.

  **Variables**                    **Category**             **Frequency**   **Percent %**
  -------------------------------- ------------------------ --------------- ---------------
  Sex                              Male                     106             48.4
  Female                           113                      51.6            
  Age                              34                       96              43.8
  35-54                            100                      45.7            
  55                               23                       10.5            
  Smear result at enrolment        Positive                 131             59.8
  Negative                         77                       35.2            
  Not indicated                    11                       5.0             
  HIV status                       Positive                 72              32.9
  Negative                         144                      65.7            
  Refused                          3                        1.4             
  Patient category                 Relapse                  159             72.6
  Retreatment after failure        43                       19.6            
  Return after loss to follow-up   17                       7.8             
  Drug regimen used                Category 1 (2ERHZ/4RH)   111             50.7
  Category 2 (2SERHZ/1ERHZ/5ERH    108                      49.3            
  Year of treatment                2014                     38              17.4
  2015                             58                       26.5            
  2016                             106                      48.4            
  2017                             17                       7.8             
  AFB result at 2 and/or 3 month   Positive                 54              24.7
  Negative                         147                      67.1            
  Not done                         16                       7.3             
  Not indicated                    2                        0.9             
  AFB result at 5th month          Positive                 49              22.4
  Negative                         160                      73.1            
  Not done                         10                       4.6             
  AFB result at 8th month          Positive                 19              8.7
  Negative                         194                      88.6            
  Not done                         6                        2.7             
  Treatment outcome                Cured                    76              34.7
  Treatment completed              70                       32.0            
  Treatment failure                47                       21.5            
  Defaulted                        1                        0.5             
  Died                             5                        2.3             
  Transferred out                  20                       9.1             

###### Treatment outcomes of TB patients by patient characteristics in Nekemte Referral Hospital, West Ethiopia, From January 2014 to December 2017 n=199.

  Characteristics                  Cure (%)                 Completed Therapy (%)   Treatment Failure (%)   Loss to Follow-up Treatment (%)   Died (%)   Total    
  -------------------------------- ------------------------ ----------------------- ----------------------- --------------------------------- ---------- -------- -----
  Sex                              Female                   27(28.1)                36(37.5)                29(30.2)                          1(1.1)     3(3.1)   96
  Male                             49(47.6)                 34(33.0)                18(17.5)                0                                 2(1.9)     103      
  Age                              34                       37(43.5)                24(28.2)                22(25.9)                          0          2(2.4)   85
  35-54                            30(32.9)                 38(41.8)                20(22.0)                0                                 3(3.3)     91       
  55                               9(39.1)                  8(34.8)                 5(21.8)                 1(4.3)                            0          23       
  HIV status                       Positive                 27(41.5)                20(30.8)                14(21.6)                          1(1.5)     3(4.6)   65
  Negative                         49(37.4)                 50(38.2)                30(22.9)                0                                 2(1.5)     131      
  Refused                          0                        0                       3(100)                  0                                 0          3        
  Smear result at enrolment        Positive                 47(402)                 39(33.3)                25(21.4)                          1(0.8)     5(4.3)   117
  Negative                         21(29.6)                 30(42.2)                20(28.2)                0                                 0          71       
  Not done                         8(72.7)                  1(9.1)                  2(18.2)                 0                                 0          11       
  Patient category                 Relapse                  57(38.5)                51(34.5)                38(25.7)                          0          2(1.3)   148
  Retreatment after failure        13(36.1)                 15(41.6)                5(13.9)                 1(2.8)                            2(5.6)     36       
  Return after loss to follow-up   6(40.0)                  4(26.7)                 4(26.7)                 0                                 1(6.6)     15       
  Drug regimen                     Category 1 (2ERHZ/4RH)   31(29.3)                37(34.9)                35(33.0)                          1(0.9)     2(1.9)   106
  Category 2 (2SERHZ/1ERHZ/5ERH)   45(48.4)                 33(35.5)                12(12.9)                0                                 3(3.2)     93       
  Year of treatment                2014                     10(31.3)                14(43.7)                8(25.0)                           0          0        32
  2015                             24(43.7)                 16(29.1)                12(21.8)                1(1.8)                            2(3.6)     55       
  2016                             38(39.6)                 34(35.4)                22(22.9)                0                                 2(2.1)     96       
  2017                             4(25.0)                  6(37.5)                 5(31.3)                 0                                 1(6.2)     16       
  AFB result at 2 and/or 3 month   Positive                 16(34.0)                15(31.9)                16(34.0)                          0          0        47
  Negative                         51(37.8)                 53(39.3)                25(18.5)                1(0.7)                            5(3.7)     135      
  Not done                         7(46.7)                  2(13.3)                 6(40.0)                 0                                 0          15       
  Not indicated                    2(100)                   0                       0                       0                                 0          2        
  AFB result at 5th month          Positive                 0                       19(46.3)                22(53.7)                          0          0        41
  Negative                         62(41.1)                 58(38.4)                25(16.6)                1(0.6)                            5(3.3)     151      
  Not done                         5(71.4)                  2(28.6)                 0                       0                                 0          7        
  AFB result at 8th month          Positive                 0                       0                       19(100)                           0          0        19
  Negative                         74(42.1)                 68(38.6)                28(15.9)                1(0.6)                            5(2.8)     176      
  Not done                         2(50)                    2(50)                   0                       0                                 0          4        

###### Logistic regression analysis of factors associated with treatment outcome in TB patients at Nekemte Referral Hospital, West Ethiopia, From January 2014 to December 2017 n=199.

  Variables                        Categories              Treatment Outcome of TB   COR (95% CI) P value   AOR (95% CI) P value    
  -------------------------------- ----------------------- ------------------------- ---------------------- ----------------------- -----------------------
  Sex                              Male                    63                        33                     2.2(1.1-4.1)p=0.018     2.1(1.0-4.4)p=0.052
  Female                           83                      20                        1                      1                       
  Age                              34                      61                        24                     1.1(0.4-3.1)p=0.838     1.6(0.4-6.5)p=0.471
  35-54                            68                      23                        1.0(0.3-2.7)p=0.936    1.5(0.4-6.0)p=0.555     
  55                               17                      6                         1                      1                       
  Smear result at enrolment        Positive                86                        31                     0.9(0.5-1.8)=0.802      \-\--
  Negative                         51                      20                        1                      \-\--                   
  HIV status                       Positive                47                        18                     1.2(0.6-2.3)p=0.622     1.3(0.6-2.8)p=0.481
  Negative                         99                      32                        1                      1                       
  Drug regimen                     Category 1(2ERHZ/4RH)   68                        38                     2.9(1.5-5.7) p=0.002    2.1(1.1-4.5)p=0.048
  Category 2(2SERHZ/1ERHZ/5ERH)    78                      15                        1                      1                       
  Year of treatment                2014                    24                        8                      0.6(0.2- 2.0)p=0.372    \-\--
  2015                             40                      15                        0.6(0.2- 2.0)p=0.432   \-\--                   
  2016                             72                      24                        0.6(0.2-1.7)p=0.300    \-\--                   
  2017                             10                      6                         1                      \-\--                   
  Patient category                 Relapse                 108                       40                     1                       \-\--
  Retreatment after failure        28                      8                         0.8(0.3-1.8)p=0.557    \-\--                   
  Return after loss to follow-up   10                      5                         1.4(0.4-4.2)p=0.604    \-\--                   
  AFB result at 2nd/3rd month      Positive                31                        16                     1.7(0.8- 3.6)p=0.137    1.2(0.5-2.6)p=0.730
  Negative                         104                     31                        1                      1                       
  AFB result at 5th month          Positive                19                        22                     4.5(2.2- 9.3)p\<0.001   4.3(1.8-10.0) p=0.001
  Negative                         120                     31                        1                      1                       
  AFB result at 8th month8         Positive                0                         19                     \_\_                    \_\_
  Negative                         142                     34                        \_\_                   \_\_                    

AOR: Adjusted Odds Ratio

COR: Crude Odds Ratio
